



PTO/SB/30 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Request For Continued Examination (RCE) Transmittal

Address to:
Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	09/738,610
Filing Date	December 15, 2000
First Named Inventor	Chyi-Cheng CHEN
Art Unit	1614
Examiner Name	B. Kwon
Attorney Docket Number	20529 C38435/111697

RECEIVED
MAY 12 2003
TECH CENTER 1600/2800

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

- a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.
- i. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on _____
- ii. ☐ Other _____
- b. ☒ Enclosed
- i. ☒ Amendment/Reply
- iii. ☐ Information Disclosure Statement (IDS)
- ii. ☐ Affidavit(s)/ Declaration(s)
- iv. ☒ Other Return Postcard

2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other _____

3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

- a. ☒ Deposit Account No. 02-4467
- i. ☐ RCE fee required under 37 CFR 1.17(e)
- ii. ☐ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☒ Other Any fees not otherwise paid
- b. ☒ Check in the amount of \$ 750.00 enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

05/12/2003 AMONDAF1 00000094 09738610

01 FC:1801

750.00 OP

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	STEPHEN J. BROWN	Registration No. (Attorney/Agent)	43,519
Signature		Date	May 5, 2003

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	STEPHEN J. BROWN	Date	May 5, 2003
Signature			

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

28.
7.
35.

Application No.: 09/738,610
Amendment Dated: May 5, 2003
Reply to Office Action of: February 5, 2003



Docket No.: 20529 (C38435/11/1697)

#13/C
JRP
5/14/03
RECEIVED
MAY 12 2003
TECH CENTER 1600/2900

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :)

Chyi-Cheng CHEN *et al.*)

Serial No.: 09/738,610)

Filed: December 15, 2000)

For: **L-ASCORBIC ACID AND PECTIN**)
COMPOSITION

Examiner: B. Kwon

Art Unit: 1614

New York, New York
May 5, 2003

SUBMISSION UNDER 37 CFR § 1.114:
RESPONSE TO FINAL OFFICE ACTION INCLUDING AMENDMENT

Mail Stop RCE
Commissioner for Patents
P.O. Box. 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Final Office Action mailed February 5, 2003. This Response is being filed concurrently with a Request for Continued Examination (RCE), and satisfies the requirement to file a "submission" under 37 CFR § 1.114(a). The Final Office Action set a three-month shortened statutory period for response. Accordingly, the RCE and Response are filed timely upon mailing, with an executed certificate of mailing, on or before May 5, 2003. 37 CFR §§ 1.8. Enclosed is a check in the amount of \$750.00 to cover the fee for the RCE. 37 CFR § 1.17. Please charge any other fees not otherwise paid by check to Deposit Account No. 02-4467. A duplicate copy of this sheet is enclosed.

Application No.: 09/738,610
Amendment Dated: May 5, 2003
Reply to Office Action of: February 5, 2003

This Response is drafted in the revised format pursuant to the procedure set forth at 1267 OG 106 in the Notice entitled "AMENDMENTS IN A REVISED FORMAT NOW PERMITTED." Accordingly, please amend the above-identified application as follows:

Amendments to the Specification: None.

Amendments to the Claims begin on page 3 of this Response, and contain a complete listing of the claims as required.

Amendments to the Drawings: None.

Remarks begin on page 7 of this Response.